ACCENDRA HEALTH INC/VA/ (ACH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 3.5B 7B 10.5B FY08: 7.2B FY09: 8B FY10: 8.1B FY11: 8.6B FY12: 8.9B FY13: 9.1B FY14: 9.4B FY15: 9.8B FY16: 9.7B FY17: 9.3B FY18: 9.4B FY19: 9.2B FY20: 8.5B FY21: 9.8B FY22: 10B FY23: 2.6B FY24: 2.7B FY25: 2.8B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 800M 1.6B 2.4B FY08: 741.1M FY09: 814.4M FY10: 807.7M FY11: 857.5M FY12: 924.7M FY13: 1.1B FY14: 1.2B FY15: 1.2B FY16: 1.2B FY17: 1.2B FY18: 1.1B FY19: 1.1B FY20: 1.3B FY21: 1.5B FY22: 1.8B FY23: 2.1B FY24: 2.2B FY08 FY10 FY12 FY14 FY16 FY18 FY20 FY22 FY24

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY08: 180.7M FY09: 201.3M FY10: 195.9M FY11: 203.5M FY12: 196.8M FY13: 198.1M FY14: 159.5M FY15: 200.4M FY16: 199.6M FY17: 89.3M FY18: -352.3M FY19: 73.2M FY20: 204.1M FY21: 368.5M FY22: 142.9M FY23: 133.2M FY24: -217.7M FY25: 27.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-1.2B -800M -400M 0 400M 800M 1.2B FY08: 93.3M FY09: 104.7M FY10: 110.6M FY11: 115.2M FY12: 109M FY13: 110.9M FY14: 66.5M FY15: 103.4M FY16: 108.8M FY17: 72.8M FY18: -437M FY19: -62.4M FY20: 29.9M FY21: 221.6M FY22: 22.4M FY23: -41.3M FY24: -362.7M FY25: -1.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 3B 6B 9B FY16: 8.5B FY17: 8.1B FY18: 8.3B FY19: 8.1B FY20: 7.2B FY21: 8.3B FY22: 8.1B FY23: 1.3B FY24: 1.4B FY25: 1.5B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-300M 0 300M 600M 900M FY08: 62.9M FY09: 218M FY10: 143.2M FY11: 68.4M FY12: 218.5M FY13: 140.6M FY14: -3.8M FY15: 270.2M FY16: 187.7M FY17: 56.8M FY18: 115.6M FY19: 166.1M FY20: 339.2M FY21: 124.2M FY22: 325M FY23: 740.7M FY24: 161.5M FY25: -101.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-400M -200M 0 200M 400M 600M FY08: 45.2M FY09: 198.3M FY10: 112M FY11: 43.4M FY12: 208.7M FY13: 112.4M FY14: -52.2M FY15: 249.7M FY16: 167.4M FY17: 22.2M FY18: 70.7M FY19: 123.7M FY20: 288.8M FY21: 83.2M FY22: 166.9M FY23: 568.3M FY24: -8.8M FY25: -292.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY09: 62.1M FY10: 62.6M FY11: 62.9M FY12: 62.8M FY13: 62.7M FY14: 62.2M FY15: 62.1M FY16: 61.1M FY17: 60M FY19: 60.6M FY20: 63.5M FY21: 75.5M FY22: 76.2M FY23: 77.4M FY24: 76.7M FY25: 76.9M FY10 FY12 FY14 FY16 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '09: 1.67 Q1 '10: 1.89 Q2 '10: 1.97 Q3 '10: 1.92 Q4 '10: 1.75 Q1 '11: 1.76 Q2 '11: 1.76 Q3 '11: 1.79 Q4 '11: 1.81 Q1 '12: 1.82 Q2 '12: 1.84 Q3 '12: 1.70 Q4 '12: 1.72 Q1 '13: 1.67 Q2 '13: 1.65 Q3 '13: 1.70 Q4 '13: 1.76 Q1 '14: 1.76 Q2 '14: 1.62 Q3 '14: 1.29 Q4 '14: 1.06 Q1 '15: 0.95 Q2 '15: 1.02 Q3 '15: 1.36 Q4 '15: 1.65 Q1 '16: 1.74 Q2 '16: 1.80 Q3 '16: 1.83 Q4 '16: 1.76 Q1 '17: 1.68 Q2 '17: 1.56 Q3 '17: 1.26 Q4 '17: 1.20 Q1 '18: 1.02 Q2 '18: -2.38 Q3 '18: -2.57 Q4 '18: -7.31 Q1 '19: -7.67 Q2 '19: -4.77 Q3 '19: -4.74 Q4 '19: -1.02 Q1 '20: -0.98 Q2 '20: -1.72 Q3 '20: -0.98 Q4 '20: 0.47 Q1 '21: 1.64 Q2 '21: 3.42 Q3 '21: 3.24 Q4 '21: 2.99 Q1 '22: 2.53 Q2 '22: 2.03 Q3 '22: 1.61 Q4 '23: -0.53 Q1 '24: -0.50 Q2 '24: -0.55 Q3 '24: -0.63 Q4 '24: -4.73 Q1 '25: -4.76 Q2 '25: -15.64 Q3 '25: -17.42 Q4 '25: -14.32 Q1 '26: -14.08 Q2 '26: -3.94 Q2 '11 Q2 '13 Q2 '15 Q2 '17 Q2 '19 Q2 '21 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.